Document is current
Any future updates will be listed below
-
Authors
Ishikawa, Emi https://orcid.org/0000-0001-8802-9438
Yokoyama, Yuta https://orcid.org/0000-0001-9359-9945
Chishima, Haruna
Kasai, Hidefumi https://orcid.org/0000-0001-5231-8027
Kuniyoshi, Ouki
Kimura, Motonori
Hakamata, Jun
Nakada, Hideo
Suehiro, Naoya
Nakaya, Naoki
Nakajima, Hideo
Ikemura, Shinnosuke https://orcid.org/0000-0002-0022-7307
Kawada, Ichiro https://orcid.org/0000-0002-8536-0018
Yasuda, Hiroyuki
Terai, Hideki
Jibiki, Aya https://orcid.org/0000-0002-9478-7419
Kawazoe, Hitoshi https://orcid.org/0000-0002-0626-7908
Soejima, Kenzo https://orcid.org/0000-0001-9749-995X
Muramatsu, Hiroshi
Suzuki, Sayo https://orcid.org/0000-0003-3094-104X
Nakamura, Tomonori https://orcid.org/0000-0001-6955-5897
-
Funding
Funding for this research was provided by:
JST SPRING (JPMJSP2123)
the Keio University Doctorate Student Grant-in-Aid Program from the Ushioda Memorial Fund
Research Foundation for Pharmaceutical Sciences
the Japan Research Foundation for Clinical Pharmacology (2018A20)
- License Information
-
More Information
Article History
Received: 31 October 2022
Revised: 29 December 2022
Accepted: 2 January 2023
First Online: 13 January 2023
Declarations
:
: This study was conducted in compliance with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the ethics committees of the Ageo Central General Hospital (Approval No. 564), Keio University School of Medicine (Approval No. 20200098), and Keio University Faculty of Pharmacy (Approval No. 210118–3 and 200710–1).
: Written informed consent for the publication of their data was obtained from all the patients who participated in this study.
: Dr. Hiroyuki Yasuda has received speaker honoraria from AstraZeneca, Brisol Meyers, and Ono, outside of the submitted work. Dr. Hitoshi Kawazoe has obtained a grant from Eli Lilly, outside of the submitted work. Dr. Kenzo Soejima has received grants from Taiho Pharmaceutical, Boehringer Ingelheim, and AstraZeneca, and speaker honoraria from Chugai, Ono Pharmaceutical, AstraZeneca, BMS, MSD, Takeda Pharmaceutical, Kyorin Pharmaceutical, Boehringer Ingelheim, Sanofi, Novartis, Eli Lilly, and Taiho Pharmaceutical, outside of the submitted work. Dr. Tomonori Nakamura has obtained grants from Astellas Pharma, Chugai, Daiichi Sankyo, Kyowa Kirin, Otsuka Pharmaceutical, Sanofi, Shionogi, and Sato Pharmaceutical, outside of the submitted work. The other authors have no relevant financial or non-financial interests to disclose.
